Definitive Contract 75A50120C00114
Award Date
5/20/20
Potential Completion Date
10/31/20
Potential Value
$126M
Awardee
Astrazeneca Pharmaceuticals LP
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Talleyville, DE 19803, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract was awarded by the Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) to AstraZeneca Pharmaceuticals LP, a foreign-owned, for-profit pharmaceutical manufacturer. The $50,194.25 firm fixed price purchase order is for vaccine storage and rotation services in Talleyville, Delaware. The award is not designated as a set-aside contract. AstraZeneca has received multiple federal contracts and cooperative agreements with HHS, the...
The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a definitive contract valued at approximately $1.1 billion to Astrazeneca Pharmaceuticals LP. The firm fixed price contract is to provide SARS-COV-2 THERAPEUTIC AZD7442 to the Department of Defense from September 2020 through September 2023. The work will be performed in South Korea. Astrazeneca Pharmaceuticals LP is the prime contractor on this contract to deliver a COVID-19 therapeutic to...
This is a $228,598,975.00 definitive cost-sharing contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Janssen Research & Development, LLC. The contract was issued under ASPR's Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) focused on the advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and...
This is a $918,380,272.80 definitive contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Phlow Corp, a for-profit pharmaceutical manufacturer, to provide U.S.-based advanced manufacturing of COVID-19 essential medicines and responses to future threats. The contract has a 10-year period of performance ending in May 2030 and uses a cost-plus-fixed-fee pricing structure. The award is funded under ASPR's...
This is a $8,650,565,549.53 Firm Fixed Price definitive contract awarded to Pfizer Inc. by the Office of the Assistant Secretary for Preparedness and Response (ASPR) for the provision of COVID-19 vaccines. The contract has an ultimate completion date of May 29, 2024 and was awarded on October 1, 2022 without any set-aside designation. Pfizer, a global pharmaceutical manufacturer, is the prime contractor for this award. The contract supports the government's COVID-19 vaccine initiatives and is...
Astrazeneca Pharmaceuticals LP was awarded a $43,631 firm fixed price delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) by the Department of Health and Human Services Indian Health Service. The contract calls for Astrazeneca to provide influenza vaccines for customers of the National Supply Service Center to support the agency's public health mission. No set-aside provisions were applied to this award. Performance will occur in Talleyville, Delaware through...
The Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $63,239,785.00 definitive contract to Arcturus Therapeutics, Inc. for the procurement of a pandemic influenza vaccine (PandFlu) and a quadrivalent seasonal influenza vaccine (QsFlu). This contract is not a set-aside and supports the Arcturus self-amplifying mRNA-based vaccine platform for rapid pandemic influenza response, a key priority under ASPR's Biomedical...
This is a federal contract award to Regeneron Pharmaceuticals Inc., a for-profit manufacturer of pharmaceuticals and therapeutics. The $692,086,314.00 award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract is for the development and production of "novel antibodies against influenza virus, emerging, re-emerging, and pre-emerging pathogens" under an Other...
This is a delivery order issued under Indefinite Delivery/Indefinite Quantity (IDIQ) contract #75A50122D00002 by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The purpose is to procure an influenza A/Astrakhan/3212/2020 (H5N8) virus vaccine candidate and conduct a clinical trial. The contract was awarded to the prime contractor, GlaxoSmithKline, LLC, a foreign-owned for-profit...
This is a $2,853,184,716.00 COVID-19 contract awarded by the Joint Program Executive Office for Chemical, Biological, Defensive (JPEO-CBD) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company. The contract is for the procurement of Sotrovimab monoclonal antibodies, an antiviral medication used to treat COVID-19. The contract does not have a set-aside designation. The prime contractor, Glaxosmithkline, LLC, has a history of federal contract awards and grants, primarily...